Limes Schlosskliniken AG
LIK
ISIN DE000A0JDBC7 / Valor 38625581
Limes Schlosskliniken AG
UMushroom community rating:
About company
Limes Schlosskliniken AG operates a network of private hospitals and clinics specializing in providing high-quality medical care and services to patients in Germany.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (07.08.2024):
Total Revenues
Limes Schlosskliniken AG reported total revenues of EUR 38.0 million for the financial year 2023, reflecting a significant increase of 26% compared to the previous year. This growth was driven by the addition of new clinic locations and an increase in the number of patients treated.
Operating Result (EBIT)
The operating result (EBIT) for Limes Schlosskliniken AG in 2023 was EUR 5.026 million, which represents a decrease of 16.2% from the previous year. This decline is attributed to investment costs for new locations and inflation-related cost increases.
Net Profit
Limes Schlosskliniken AG's consolidated net income for the period was EUR 3.396 million, down 19.2% from the previous year. Despite the decrease, the company plans to reinvest the net profit to strengthen its position and capitalize on future opportunities.
Equity and Assets
The equity of Limes Schlosskliniken AG increased by 48.7% to EUR 16.643 million in 2023. Long-term assets also saw a significant rise of 64.6%, reaching EUR 18.211 million, while short-term assets slightly decreased by 3.5% to EUR 15.037 million.
Employee Growth
As of the end of 2023, Limes Schlosskliniken AG employed 207 people, marking an 18.3% increase from the previous year. This growth in staff is in line with the company's expansion and increased patient occupancy rates.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
103 M
Market cap (USD)
17
Daily traded volume (Shares)
334 / 334
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
